Business Context and Reporting Period
Company: CRISPR Therapeutics AG (CRSP)
Filing Type: Form 8-K (Current Report)
Date of Report: May 19, 2025
Event: Entry into a Material Definitive Agreement with Sirius Therapeutics (Sirius-CY and Sirius-US).
Key Financial Metrics and Transaction Terms
This filing details a strategic collaboration rather than standard periodic financial results. Key financial terms include:
- Upfront Consideration:
- Cash Payment: $25.0 million.
- Equity Issuance: Approximately $70.0 million in common shares (1,842,105 shares at $38.00 per share).
- Collaboration Products (Factor XI siRNA):
- Cost Sharing: Development and commercialization costs shared equally.
- Profit/Loss Sharing: Net profits and losses shared equally.
- Milestones: Up to $87.5 million payable by CRISPR to Sirius (cash, shares, or combination).
- Opt-Out Royalties: Mid-single to low-double digit tiered royalties if a party opts out.
- Licensed Products (Up to 2 Targets):
- Option Fee: $10.0 million per option (payable up to 2 times).
- Milestones: Up to $300.0 million per licensed target.
- Royalties: Mid-single to low-double digit tiered royalties on net sales.
- Responsibility: CRISPR bears all costs for research, development, and commercialization.
Material Changes and Strategic Developments
The primary material change is the establishment of a joint venture-like structure for Factor XI (FXI) inhibition:
- Joint Steering Committee (JSC): Established with equal representation; CRISPR retains final decision-making authority on Licensed Products after option exercise.
- Commercialization Roles: For the first collaboration product, CRISPR leads in the U.S., while Sirius leads in Greater China. Global leadership for other regions to be determined.
- Exclusivity: Neither party may advance siRNA products targeting Factor XI outside this agreement while collaboration products are commercialized.
Outlook, Management Commentary, and Clinical Data
Product Focus: SRSD107, a next-generation, long-acting siRNA targeting Factor XI to reduce thrombotic events with minimal bleeding risk.
- Clinical Progress: Two Phase 1 trials completed. Single doses were well tolerated.
- Pharmacodynamics: Demonstrated >93% reduction in FXI levels/activity and >2x increase in activated partial thromboplastin time. Effects sustained for up to six months.
- Next Steps: Initiation of a Phase 2 trial for venous thromboembolism prevention in total knee arthroplasty patients.
- Target Indications: Atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, chronic coronary/peripheral vascular disease, end-stage renal disease, and major orthopedic surgery.
Investor Verification Checklist
- Verify the final closing of the $70.0 million share issuance and the $25.0 million cash payment.
- Monitor the timeline for the initiation of the Phase 2 clinical trial for SRSD107.
- Review the specific "reserved targets" list for the Licensed Products options to assess pipeline expansion potential.
- Track the formation and first meeting minutes of the Joint Steering Committee (JSC).
- Confirm the specific terms regarding the "opt-out" rights and associated milestone caps in the full agreement text (Exhibit 10.1).